H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Solid Biosciences today and set a price target of $20.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arthur He CFA has given his Buy rating due to a combination of factors related to SGT-003’s emerging best-in-class profile. The Phase 1/2 INSPIRE DUCHENNE data show strong and consistent micro-dystrophin expression across a doubled patient cohort, alongside meaningful reductions in markers of muscle damage and clear signs of muscle preservation and restoration of the dystrophin-associated protein complex.
He also highlights encouraging cardiac signals, including stabilized or improved ejection fraction over time, and a safety profile that has improved as the treated population expanded, with only one resolved treatment-related serious event and no major liver or thrombotic complications. Looking ahead, protocol refinements aimed at boosting expression have not yet been fully reflected in the biopsy data, and upcoming FDA interactions regarding a potential accelerated approval pathway provide additional upside optionality for shareholders.